Evolus (NASDAQ:EOLS) Shares Gap Up – Here’s What Happened

Evolus, Inc. (NASDAQ:EOLS) shares gapped up prior to trading on Tuesday . The stock had previously closed at $10.51, but opened at $12.98. Evolus shares last traded at $13.57, with a volume of 865,474 shares changing hands.

Wall Street Analysts Forecast Growth

EOLS has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of Evolus in a report on Wednesday. Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Evolus in a research note on Tuesday.

Evolus Price Performance

The firm has a market capitalization of $894.71 million, a price-to-earnings ratio of -15.53 and a beta of 1.32. The company’s 50 day moving average is $11.70 and its 200 day moving average is $13.75. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58.

Institutional Investors Weigh In On Evolus

Several institutional investors have recently made changes to their positions in the stock. KBC Group NV bought a new position in Evolus in the 4th quarter valued at about $49,000. Quarry LP acquired a new stake in shares of Evolus during the 2nd quarter worth approximately $54,000. Profund Advisors LLC bought a new position in Evolus in the second quarter valued at approximately $130,000. Point72 Asset Management L.P. acquired a new position in Evolus during the third quarter valued at approximately $132,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Evolus during the third quarter valued at approximately $191,000. 90.69% of the stock is currently owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.